UNIGE document Scientific Article
previous document  unige:99092  next document
add to browser collection

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

Maury, Sébastien
Chevret, Sylvie
Thomas, Xavier
Heim, Dominik
Leguay, Thibaut
Huguet, Françoise
Chevallier, Patrice
Hunault, Mathilde
show hidden authors show all authors [1 - 22]
Published in New England Journal of Medicine. 2016, vol. 375, no. 11, p. 1044-1053
Abstract Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial.
Keywords AdolescentAdultAntigens, CD20/analysisAntineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic useDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/immunologyPrognosisRemission InductionRituximab/administration & dosage/adverse effectsYoung Adult
PMID: 27626518
Full text
Article (Published version) (294 Kb) - public document Free access
Research group Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982)
(ISO format)
MAURY, Sébastien et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. In: New England Journal of Medicine, 2016, vol. 375, n° 11, p. 1044-1053. doi: 10.1056/NEJMoa1605085 https://archive-ouverte.unige.ch/unige:99092

271 hits



Deposited on : 2017-11-16

Export document
Format :
Citation style :